stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Shares outstanding
Relay Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $171.6M, up 20.1% from $142.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $202.8M. Over the past ten years it has ranged from $3.5M (fiscal 2019) to $171.6M (fiscal 2025) — the current reading is the highest in ten years. Relay Therapeutics, Inc. ranks 47th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $171.6M | 20.10% |
| FY2024 | $142.9M | 16.55% |
| FY2023 | $122.6M | 9.22% |
| FY2022 | $112.2M | 17.97% |
| FY2021 | $95.1M | 123.22% |
| FY2020 | $42.6M | 1,134.99% |
| FY2019 | $3.5M | (96.16%) |
| FY2018 | $89.9M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $202.8M | 12.79% |
| Mar 2026 | $179.8M | 4.82% |
| Dec 2025 | $171.6M | (0.47%) |
| Sep 2025 | $172.4M | 0.66% |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. compare | $450.2M |
| ABCL AbCellera Biologics Inc. compare | $305.6M |
| RLAY Relay Therapeutics, Inc. | $202.8M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| TNGX Tango Therapeutics, Inc. compare | $149.9M |
| EWTX Edgewise Therapeutics, Inc. compare | $107.7M |
| XENE Xenon Pharmaceuticals Inc. compare | $99.6M |
| IRON Disc Medicine, Inc. compare | $38.7M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement